research use only
Cat.No.S7609
| Related Targets | Bcl-2 Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras |
|---|---|
| Other Phospholipase (e.g. PLA) Inhibitors | Varespladib (LY315920) Darapladib (SB-480848) U-73122 Tanshinone I Quinacrine 2HCl (E/Z)-Polydatin Melittin Trigonelline FIPI CAY10593 (VU0155069) |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| MCF7 | Function assay | 10-20 μM | the addition of 10 μM GW4869 significantly inhibited TNF-induced SM hydrolysis, whereas 20 μM of the compound protected completely from the loss of sphingomyelin | 12154098 | ||
| OPM2 | Proliferation assay | 0, 1.25, 2.5, 5, 10, 20, 40 μmol/L | 24 h | the cell proliferation rate was increased after GW4869 treatment. The inhibition of cell proliferation was only significant when the concentration of GW4869 was 40 μmol/L or higher. | 28858294 | |
| RPMI-8226 | Cell viability assay | 72 h | cytotoxic to a panel of MM cell lines | 28211573 | ||
| NCI-H929 | Cell viability assay | 72 h | cytotoxic to a panel of MM cell lines | 28211573 | ||
| JJN3 | Cell viability assay | 72 h | cytotoxic to a panel of MM cell lines | 28211573 | ||
| U266 | Cell viability assay | 72 h | cytotoxic to a panel of MM cell lines | 28211573 | ||
| Daudi | Cell viability assay | 72 h | not cytotoxic to non-MM cell lines or PBMCs | 28211573 | ||
| Jurkat | Cell viability assay | 72 h | not cytotoxic to non-MM cell lines or PBMCs | 28211573 | ||
| K562 | Cell viability assay | 72 h | not cytotoxic to non-MM cell lines or PBMCs | 28211573 | ||
| PBMCs | Cell viability assay | 72 h | not cytotoxic to non-MM cell lines or PBMCs | 28211573 | ||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 1 mg/mL
(1.73 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 577.5 | Formula | C30H28N6O2.2HCl.XH2O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 6823-69-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | GW69A, GW554869A | Smiles | C1CN=C(N1)C2=CC=C(C=C2)NC(=O)C=CC3=CC=C(C=C3)C=CC(=O)NC4=CC=C(C=C4)C5=NCCN5.Cl.Cl | ||
| Targets/IC50/Ki |
SMase
(Cell-free assay) 1 μM
|
|---|---|
| In vitro |
GW4869 inhibits N-SMase not only in vitro but also in a cellular model. This compound does not significantly impair TNF-induced NF-κB translocation to nuclei. Therefore, it does not interfere with other key TNF-mediated signaling effects. It is able, in a dose-dependent manner, to significantly protect from cell death as measured by nuclear condensation, caspase activation, PARP degradation, and trypan blue uptake. These protective effects are accompanied by significant inhibition of cytochrome c release from mitochondria and caspase 9 activation, therefore localizing N-SMase activation upstream of mitochondrial dysfunction. At up to 150 μM, this chemical does not inhibit the cloned human A-SMase. It shows no or minor inhibitory activity versus other hydrolytic enzymes, such as bacterial phosphatidylcholine-PLC and bovine protein phosphatase 2A, and it shows significantly higher activity versus the rat brain enzyme compared with the human lyso-PAF PLC.
|
| In vivo |
Systemic administration of GW4869 does not alter the ceramide or sphingomylein content of liver, heart or skeletal muscle but does decrease the ceramide content and increase the sphingomyelin content in brain. Inhibition of nSMase2 with this compound slowed learning. Mice administered this chemical do not progressively decrease latency to locate the hidden platform with repeated training trials, suggesting that they has difficulty learning to use spatial cues to navigate the pool. Intraperitoneal injection of this agent reduces the levels of brain and serum exosomes, brain ceramide, and Aβ1-42 plaque load. It reduces amyloid plaque formation in vivo by preventing exosome secretion. This inhibitor may have a low toxicity at levels needed to achieve a biological effect from nSMase2 inhibition.
|
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Immunofluorescence | Nrf2 |
|
29794115 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.